Keytruda's New Tissue-Agnostic Indication Could Prompt Orphan Policy Changes
US FDA contemplating how to match orphan designation process with drug development moving to molecularly-targeted therapies.
US FDA contemplating how to match orphan designation process with drug development moving to molecularly-targeted therapies.